Encircling the regions of the pharmacogenomic landscape that determine drug response.


Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
26 03 2019
Historique:
received: 17 10 2018
accepted: 05 03 2019
entrez: 28 3 2019
pubmed: 28 3 2019
medline: 28 12 2019
Statut: epublish

Résumé

The integration of large-scale drug sensitivity screens and genome-wide experiments is changing the field of pharmacogenomics, revealing molecular determinants of drug response without the need for previous knowledge about drug action. In particular, transcriptional signatures of drug sensitivity may guide drug repositioning, prioritize drug combinations, and point to new therapeutic biomarkers. However, the inherent complexity of transcriptional signatures, with thousands of differentially expressed genes, makes them hard to interpret, thus giving poor mechanistic insights and hampering translation to clinics. To simplify drug signatures, we have developed a network-based methodology to identify functionally coherent gene modules. Our strategy starts with the calculation of drug-gene correlations and is followed by a pathway-oriented filtering and a network-diffusion analysis across the interactome. We apply our approach to 189 drugs tested in 671 cancer cell lines and observe a connection between gene expression levels of the modules and mechanisms of action of the drugs. Further, we characterize multiple aspects of the modules, including their functional categories, tissue-specificity, and prevalence in clinics. Finally, we prove the predictive capability of the modules and demonstrate how they can be used as gene sets in conventional enrichment analyses. Network biology strategies like module detection are able to digest the outcome of large-scale pharmacogenomic initiatives, thereby contributing to their interpretability and improving the characterization of the drugs screened.

Sections du résumé

BACKGROUND
The integration of large-scale drug sensitivity screens and genome-wide experiments is changing the field of pharmacogenomics, revealing molecular determinants of drug response without the need for previous knowledge about drug action. In particular, transcriptional signatures of drug sensitivity may guide drug repositioning, prioritize drug combinations, and point to new therapeutic biomarkers. However, the inherent complexity of transcriptional signatures, with thousands of differentially expressed genes, makes them hard to interpret, thus giving poor mechanistic insights and hampering translation to clinics.
METHODS
To simplify drug signatures, we have developed a network-based methodology to identify functionally coherent gene modules. Our strategy starts with the calculation of drug-gene correlations and is followed by a pathway-oriented filtering and a network-diffusion analysis across the interactome.
RESULTS
We apply our approach to 189 drugs tested in 671 cancer cell lines and observe a connection between gene expression levels of the modules and mechanisms of action of the drugs. Further, we characterize multiple aspects of the modules, including their functional categories, tissue-specificity, and prevalence in clinics. Finally, we prove the predictive capability of the modules and demonstrate how they can be used as gene sets in conventional enrichment analyses.
CONCLUSIONS
Network biology strategies like module detection are able to digest the outcome of large-scale pharmacogenomic initiatives, thereby contributing to their interpretability and improving the characterization of the drugs screened.

Identifiants

pubmed: 30914058
doi: 10.1186/s13073-019-0626-x
pii: 10.1186/s13073-019-0626-x
pmc: PMC6436215
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17

Subventions

Organisme : European Research Council
ID : 614944
Pays : International

Références

J Biol Chem. 1998 Mar 6;273(10):5908-15
pubmed: 9488729
J Mol Biol. 2018 Sep 14;430(18 Pt A):3016-3027
pubmed: 29626539
Nat Rev Drug Discov. 2018 May;17(5):317-332
pubmed: 29472638
Nature. 1999 Dec 2;402(6761 Suppl):C47-52
pubmed: 10591225
Nat Rev Genet. 2007 Aug;8(8):601-9
pubmed: 17607306
J Biomol Screen. 2014 Jun;19(5):771-81
pubmed: 24464433
Biomolecules. 2017 Jul 11;7(3):
pubmed: 28696357
Nature. 2013 Dec 19;504(7480):389-93
pubmed: 24284626
PLoS Comput Biol. 2015 Apr 08;11(4):e1004120
pubmed: 25853560
Trends Cell Biol. 1998 Mar;8(3):101-6
pubmed: 9695818
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6213-7
pubmed: 8327501
Cancer Lett. 2005 Jun 1;223(1):1-10
pubmed: 15890231
Annu Rev Pharmacol Toxicol. 2005;45:51-88
pubmed: 15822171
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Nat Genet. 2015 Feb;47(2):106-14
pubmed: 25501392
Nat Biotechnol. 2007 Feb;25(2):197-206
pubmed: 17287757
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Nat Rev Genet. 2011 Jan;12(1):56-68
pubmed: 21164525
Genome Med. 2018 Aug 3;10(1):61
pubmed: 30071882
Nat Genet. 2016 Aug;48(8):838-47
pubmed: 27322546
J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
pubmed: 2041050
Drug Metab Dispos. 2010 Feb;38(2):347-56
pubmed: 19923256
Surgery. 2007 Apr;141(4):464-9
pubmed: 17383523
Nat Commun. 2017 Oct 30;8(1):1186
pubmed: 29084964
Matrix Biol. 2014 Feb;34:144-53
pubmed: 24184828
Nature. 1997 Dec 11;390(6660):632-6
pubmed: 9403696
J Invest Dermatol. 2009 May;129(5):1061-3
pubmed: 19369932
Nat Commun. 2018 Jan 3;9(1):42
pubmed: 29298978
Ann Oncol. 2009 Nov;20(11):1813-7
pubmed: 19553291
Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19
pubmed: 21701501
Nat Chem Biol. 2016 Feb;12(2):109-16
pubmed: 26656090
Nat Commun. 2015 Oct 27;6:8746
pubmed: 26503059
Cancer Cell. 2012 Sep 11;22(3):304-17
pubmed: 22975374
Carcinogenesis. 2012 Oct;33(10):1965-75
pubmed: 22791812
J Neurosci. 2009 Jan 21;29(3):775-88
pubmed: 19158303
Sci Rep. 2016 Feb 08;6:20395
pubmed: 26854061
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Cancer Lett. 2007 Mar 8;247(1):1-25
pubmed: 16725254
Nat Rev Drug Discov. 2011 Jun;10(6):428-38
pubmed: 21629293
Diabetologia. 1997 Jul;40 Suppl 2:S25-31
pubmed: 9248698
Toxicology. 2018 Jul 1;404-405:25-32
pubmed: 29729928
Lab Invest. 2016 Feb;96(2):137-50
pubmed: 26641068
Oncogenesis. 2018 Jan 24;7(1):8
pubmed: 29362397
Am J Cancer Res. 2016 Mar 15;6(4):827-42
pubmed: 27186434
Sci Rep. 2015 Feb 03;5:7835
pubmed: 25644501
Mol Cancer Ther. 2018 Dec;17(12):2551-2563
pubmed: 30217967
Curr Opin Cell Biol. 2003 Dec;15(6):740-6
pubmed: 14644200
Oncogene. 2016 Sep 29;35(39):5119-31
pubmed: 26999641
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):10911-6
pubmed: 25024206
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72
pubmed: 16381955
Genome Res. 2017 Oct;27(10):1743-1751
pubmed: 28847918
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Cell. 2013 Mar 18;23(3):302-15
pubmed: 23477830
Ther Adv Med Oncol. 2014 Jul;6(4):154-66
pubmed: 25057302
Semin Cancer Biol. 2002 Jun;12(3):197-207
pubmed: 12083850
Mol Cancer. 2015 Feb 15;14:40
pubmed: 25881072
Br J Cancer. 2011 Nov 8;105(10):1554-62
pubmed: 21970876
Clin Cancer Res. 2014 May 1;20(9):2257-63
pubmed: 24610826
Cancer Res. 2005 May 1;65(9):3596-603
pubmed: 15867353
Mol Syst Biol. 2009;5:256
pubmed: 19357636
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Adv Biol Regul. 2015 Sep;59:65-81
pubmed: 26257206
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61
pubmed: 23180760
BMC Bioinformatics. 2009 Jul 29;10:234
pubmed: 19640299
Mol Cancer. 2006 Aug 09;5:31
pubmed: 16899113
Int J Biochem Cell Biol. 2015 May;62:101-14
pubmed: 25747905
Nature. 2016 Nov 30;540(7631):E1-E2
pubmed: 27905415
Nucleic Acids Res. 2015 Dec 15;43(22):10588-601
pubmed: 26546517
J Comput Biol. 2011 Mar;18(3):507-22
pubmed: 21385051
Science. 2015 Feb 20;347(6224):1257601
pubmed: 25700523
J Endocrinol. 2011 May;209(2):139-51
pubmed: 21307119
Nucleic Acids Res. 2018 Jan 4;46(D1):D994-D1002
pubmed: 30053271
Bioinformatics. 2017 Nov 15;33(22):3610-3618
pubmed: 29036404
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
Nature. 2012 Mar 28;483(7391):570-5
pubmed: 22460902
Science. 1993 Jun 11;260(5114):1658-61
pubmed: 8503013
Target Oncol. 2016 Jun;11(3):371-81
pubmed: 26668065
Cancer Discov. 2015 Nov;5(11):1210-23
pubmed: 26482930
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Genome Biol. 2014 Mar 03;15(3):R47
pubmed: 24580837
Mol Cell. 2017 Jan 5;65(1):142-153
pubmed: 27989436
Nature. 2015 Dec 3;528(7580):84-7
pubmed: 26570998
Front Genet. 2013 May 31;3:227
pubmed: 23755063
Nature. 2009 Sep 10;461(7261):218-23
pubmed: 19741703
Oncotarget. 2015 Apr 20;6(11):9189-205
pubmed: 25826077
Genes (Basel). 2013 Mar 26;4(2):101-33
pubmed: 24705157
Sci Rep. 2016 Mar 10;6:22811
pubmed: 26960563
J Neurooncol. 2010 Jan;96(2):169-79
pubmed: 19609742
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505

Auteurs

Adrià Fernández-Torras (A)

Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain.

Miquel Duran-Frigola (M)

Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain. miquel.duran@irbbarcelona.org.

Patrick Aloy (P)

Joint IRB-BSC-CRG Program in Computational Biology, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Catalonia, Spain. patrick.aloy@irbbarcelona.org.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain. patrick.aloy@irbbarcelona.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH